Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

Key Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.

Bibliographic Details
Main Authors:	Si‐Man Huang, Chao‐Ling Wan, Han‐Yu Cao, Yan‐Yan Li, Chong‐Sheng Qian, Hai‐Xia Zhou, Ming‐Zhu Xu, Xiao‐Hui Hu, Lan Dai, Hai‐Ping Dai, Sheng‐Li Xue
Format:	Article
Language:	English
Published:	Wiley 2023-12-01
Series:	Clinical Case Reports
Subjects:	B‐ALL CD22 inotuzumab ozogamicin MRD positive relapsed and refractory
Online Access:	https://doi.org/10.1002/ccr3.8289

Similar Items

Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
by: Jeremy D. Rubinstein, et al.
Published: (2023-08-01)

Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
by: Yurkiewicz IR, et al.
Published: (2018-07-01)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
by: Uy N, et al.
Published: (2018-04-01)

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
by: Luca Bertamini, et al.
Published: (2018-11-01)

Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study
by: Nicola Stefano Fracchiolla, et al.
Published: (2023-09-01)

Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
by: David I. Marks, et al.
Published: (2019-10-01)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
by: Amandeep Aujla, et al.
Published: (2019-04-01)

Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
by: Warren Fingrut, et al.
Published: (2020-12-01)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
by: Tomoaki Ueda, et al.
Published: (2022-01-01)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
by: Elena Tirrò, et al.
Published: (2019-02-01)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
by: Fabio Giglio, et al.
Published: (2022-06-01)

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
by: Darshana Jani, et al.
Published: (2018-02-01)

CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
by: Francesco Lanza, et al.
Published: (2020-01-01)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
by: Hagop Kantarjian, et al.
Published: (2023-05-01)

Total body irradiation-based haploidentical hematopoietic stem cell transplantation using posttransplant cyclophosphamide after administration of inotuzumab ozogamicin: A case report
by: Masaya Abe, et al.
Published: (2021-01-01)

Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children—the Polish Pediatric Leukemia and Lymphoma Study Group experience
by: Katarzyna Pawinska-Wasikowska, et al.
Published: (2023-12-01)

Novel Immunotherapy Agents for Acute Lymphoblastic Leukaemia
by: David Pesántez, et al.
Published: (2017-08-01)

Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia
by: Zheng Shi, et al.
Published: (2022-12-01)

Very rare near‐haploid acute lymphoblastic leukemia resistant to immunotherapy and CAR‐T therapy in 19‐year‐old male patient
by: Tomas Arpas, et al.
Published: (2022-03-01)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
by: Bachar Samra, et al.
Published: (2020-06-01)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
by: Hien K Duong, et al.
Published: (2009-05-01)

Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
by: Alexander Russell-Smith, et al.
Published: (2023-12-01)

Targeting CD22 for the Treatment of B-Cell Malignancies
by: Shah NN, et al.
Published: (2021-07-01)

First case of near haploid philadelphia negative B-Cell acute lymphoblastic leukaemia relapsing as acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
by: Claire Horgan, et al.
Published: (2020-01-01)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
by: Lee KJ, et al.
Published: (2016-08-01)

Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey
by: Ayşe Hilal Eroğlu Küçükdiler, et al.
Published: (2021-01-01)

Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
by: Varadarajan I, et al.
Published: (2023-01-01)

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
by: Bo Yu, et al.
Published: (2019-09-01)

Optimal Use of Novel Immunotherapeutics in B-Cell Precursor ALL
by: Federico Lussana, et al.
Published: (2023-02-01)

Case Report: Precision Medicine Target Revealed by In Vitro Modeling of Relapsed, Refractory Acute Lymphoblastic Leukemia From a Child With Neurofibromatosis
by: Susan L. Heatley, et al.
Published: (2022-04-01)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
by: Michele Gottardi, et al.
Published: (2021-09-01)

Mutational profiling of acute lymphoblastic leukemia with testicular relapse
by: Ling-Wen Ding, et al.
Published: (2017-03-01)

A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia
by: Jianyu Weng, et al.
Published: (2018-02-01)

Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
by: Qingqing Zheng, et al.
Published: (2020-11-01)

The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience
by: İbrahim Halil Açar, et al.
Published: (2023-03-01)

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia
by: Enrico Maffini, et al.
Published: (2019-05-01)

Corrigendum: Down-Regulated FOXO1 in Refractory/Relapse Childhood B-Cell Acute Lymphoblastic Leukemia
by: Qingqing Zheng, et al.
Published: (2020-12-01)

Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis
by: Jun Li, et al.
Published: (2022-12-01)

Immunophenotypic Modulation of the Blast Cells in Childhood Acute Lymphoblastic Leukemia Minimal Residual Disease Detection
by: Burnusuzov Hasan A., et al.
Published: (2016-03-01)

Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases
by: Letitia-Elena Radu, et al.
Published: (2020-06-01)